Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: PuddleGlum who wrote (1637)	9/15/2000 1:06:05 AM
From: greedsgd_2000	Respond to of 52153

MYGN is about identification of GENETIC predispositions to certain cancers (e.g. breast cancer) whereas NMPS is about ultra-early discovery of malignancy markers for certain cancers. These are quite different of course. The two categories interact however, as those individuals once identified as genetically predisposed - would forever be in a watchful waiting type mode -thus perfect candidates for stepped up use of noninvasive NMP style blood tests. In addition, genetic testing per targeted gene would in essence be a one time event, whereas NMP type marker tests would be repeated on a periodic schedule as part of a wide scale screening program - at a rate determined by among other things - discretion, risk factors, or demographics. Gilder as you might realize is valuation agnostic,(at least in theory) however his (or his team's focus to be more precise) on biotechs obviously will help the whole sector. Now on the subject of valuation, CEGE appears significantly undervalued relative to its ABGX holdings plus cash position. Combined, they nearly equal the market cap.